Chemoproteomics uses small-molecule chemical probes combined with mass spectrometry to figure out which proteins a drug or compound actually touches inside living cells. The field has become central to modern drug discovery because it answers a question that traditional biochemistry often cannot: out of the tens of thousands of proteins in a cell, which ones does a given molecule bind, and where? What makes the field especially dynamic right now is the rapid expansion of both probe-based and probe-free strategies, each with trade-offs in sensitivity, throughput, and the degree to which they preserve the messy reality of a living cell.
How Probe-Based Chemoproteomics Works
The original and still most widely used chemoproteomic approaches rely on chemical probes. A probe is essentially a modified version of the molecule you are interested in, fitted with reactive tags that let you fish out whichever proteins the molecule sticks to. Once those proteins are captured, mass spectrometry identifies them. The canonical methods use probes that engage a target, enrich it by pulling it out of a complex protein mixture, and then identify it through sequencing of the captured proteins.1PubMed Central. Chemoproteomics, A Broad Avenue to Target Deconvolution Two technical innovations have pushed these methods forward: click chemistry, which lets researchers snap molecular pieces together inside cells with high precision, and photoaffinity labeling, which uses light to lock a probe onto its protein partner at the exact moment of binding.
Activity-based protein profiling, or ABPP, is one of the most mature forms of probe-based chemoproteomics. Instead of simply asking whether a protein is present, ABPP asks whether a protein is functionally active. The probes used in ABPP have a “warhead” that reacts only with the active form of a protein, so you get a readout not just of what is there but of what is switched on.2PubMed Central. Activity-based protein profiling: A graphical review That distinction matters enormously in disease biology, where the same enzyme can be abundant but inactive, or scarce but hyperactive.
Photoaffinity Labeling and Capturing Weak Interactions
Many biologically important protein-ligand interactions are weak or fleeting. A drug might brush up against dozens of proteins, spending milliseconds with each, and standard pull-down methods miss those encounters. Photoaffinity labeling addresses this by incorporating a light-sensitive group into the probe. When you flash UV light, the group generates a highly reactive intermediate (often a carbene) that instantly forms a covalent bond with whatever protein is nearby at that moment, freezing the interaction in place.3PubMed. Recent advances in photoaffinity labeling strategies to capture Glycan-Protein interactions
The chemistry behind this is more nuanced than it first appears. Dialkyldiazirines, the most popular photoaffinity groups used in biological studies, do not operate through a single clean mechanism. Research has shown that both carbene and diazo pathways contribute to labeling, with different chemical selectivities and reaction speeds. Carbene insertions are nearly instantaneous, while competing diazo-mediated pathways are slower, which can complicate the interpretation of results.4Organic Letters. Probing the Mechanism of Photoaffinity Labeling by Dialkyldiazirines through Bioorthogonal Capture of Diazoalkanes Understanding these mechanistic subtleties helps researchers design better probes and avoid artifacts.
Label-Free Methods That Skip the Probe Entirely
Probe-based approaches have a fundamental limitation: you have to chemically modify the molecule of interest. Attaching a tag can change how a compound behaves, sometimes altering its binding properties or cellular uptake. This is a problem when you want to study the exact molecule that hits a patient’s cells. Label-free chemoproteomic methods get around this by detecting changes in protein behavior when a drug is present, without modifying the drug at all.
The cellular thermal shift assay, or CETSA, exploits a straightforward physical principle. When a small molecule binds to a protein, it typically stabilizes the protein’s structure, making it more resistant to heat. By gradually heating cell lysates (or intact cells) in the presence and absence of a compound and then measuring which proteins stay folded longer, you can identify the targets of an unmodified drug.5PubMed Central. Applications of the Cellular Thermal Shift Assay to Drug Discovery in Natural Products: A Review Pairing CETSA with mass spectrometry has made it possible to measure thermal stability shifts across thousands of proteins simultaneously, turning what was once a one-target-at-a-time experiment into a proteome-wide screen.6PubMed. Mass spectrometry-based Cellular Thermal Shift Assay (CETSA®) for target deconvolution in phenotypic drug discovery
Another label-free approach, drug affinity responsive target stability (DARTS), relies on proteolysis rather than heat. When a drug binds a protein, the bound region becomes partially shielded from digestive enzymes. By adding a protease to cell extracts treated with or without the compound and then comparing which proteins survive digestion, researchers can identify targets without any chemical modification of the drug.7PubMed Central. Drug affinity responsive target stability (DARTS) for small-molecule target identification DARTS is appealing for its simplicity and the fact that it works with the native compound, but it tends to be less sensitive than probe-based methods for low-abundance targets.8PubMed Central. Target identification using drug affinity responsive target stability (DARTS)
Cleavable Linkers and the Sample Preparation Problem
A persistent headache in chemoproteomics is background noise. When you pull a target protein out of a cell extract, you inevitably drag along thousands of non-specific bystander proteins that stuck to the beads, the linker, or each other. Cleavable linkers help solve this. These are molecular connectors between the probe and the capture tag that can be snapped open on command, releasing only the specifically bound proteins while leaving background contaminants behind on the bead.
Different cleavage triggers have been developed for different experimental needs, including acid, base, redox chemistry, and light.9PubMed Central. Targeting the Reactive Proteome: Recent Advances in Activity-Based Protein Profiling and Probe Design One early and elegant example uses a vicinal diol group that can be cleaved with sodium periodate, substantially reducing the number of background protein identifications compared with standard methods.10PubMed Central. A simple and effective cleavable linker for chemical proteomics applications A comparative study of different cleavable linkers found that enriching peptides after protein digestion, rather than before, yielded far more identified cysteine residues. That optimization, combined with multiplexed quantitative labeling, enabled the detection and quantification of over 10,000 unique cysteine sites in a single experiment.11PubMed. Evaluation of Chemically-Cleavable Linkers for Quantitative Mapping of Small Molecule-Cysteinome Reactivity
More recently, platforms like sCIP-TMT have streamlined the workflow further by allowing early sample pooling, cutting preparation time while maintaining high quantitative accuracy across a ten-plex set of samples.12Communications Chemistry. Functionalizing tandem mass tags for streamlining click-based quantitative chemoproteomics These incremental improvements in sample handling and quantification have collectively transformed chemoproteomics from a specialist technique into something approaching a scalable drug discovery platform.
Mapping the Druggable Proteome Beyond Cysteine
For years, chemoproteomic ligand discovery focused heavily on cysteine residues. Cysteine is the most chemically reactive amino acid commonly found on protein surfaces, making it a natural target for covalent probes. Drugs like the cancer therapy osimertinib work by latching permanently onto a cysteine in their target. But cysteines are relatively rare, and many important disease targets lack an accessible one.
The field is now expanding to other amino acids. Lysine, which is about three times more abundant in the human proteome than cysteine, has received substantial attention as a covalent labeling target. Newer probe chemistries have also enabled functional profiling of tyrosine residues across more than 10,000 unique sites from roughly 3,700 protein targets in human cells. Warheads targeting histidine have been developed using chemical handles like 2-cyclohexenone and sulfonyl-fluoride compounds.13Trends in Pharmacological Sciences. Chemoproteomics: Research Strategies and New Perspectives – Section: Advances in covalent fragment electrophiles and chemistries targeting amino acid residues beyond cysteine This expansion of targetable residues effectively opens new territory in the proteome that was previously off-limits to covalent drug design.14PubMed. Expanding the landscape of covalent drug discovery: irreversible targeting of non-cysteine residues
Within the cysteine space itself, the picture is also getting sharper. Different probes reveal different slices of the “cysteinome.” Comparative profiling using the isoTOP-ABPP method showed that while widely used probes cover a large common set of cysteines, each probe also uniquely detects a subset of hyper-reactive cysteines that the other misses.15Current Research in Chemical Biology. Comparative reactivity profiling of cysteine-specific probes by chemoproteomics Newer probes like NAIA (N-acryloylindole-alkyne) have been designed with improved cysteine reactivity, outperforming the conventional iodoacetamide-based probes and even enabling imaging of oxidized thiols by fluorescence microscopy.16PubMed Central. N-Acryloylindole-alkyne (NAIA) enables imaging and profiling new ligandable cysteines and oxidized thiols by chemoproteomics
Finding Off-Targets and Explaining Drug Side Effects
One of the most immediately practical applications of chemoproteomics is figuring out why drugs cause unexpected side effects. A kinase inhibitor designed to block one enzyme often binds others, and profiling the full target landscape reveals off-target interactions that clinical observation alone cannot explain.
A striking example involved testing 226 clinical kinase inhibitors for their ability to bind ferrochelatase, an enzyme involved in heme production that has nothing to do with kinase signaling. Of the 226 compounds tested, 29 showed low- or sub-micromolar binding to ferrochelatase, and several of these (including vemurafenib and neratinib) were confirmed to reduce heme levels in cells. Because genetic loss of ferrochelatase activity causes photosensitivity in humans, these findings strongly suggested that ferrochelatase inhibition is the molecular mechanism behind the skin photosensitivity that some patients experience on these drugs.17PubMed. Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors That kind of mechanistic clarity can guide the design of next-generation compounds that spare the off-target or inform clinical monitoring for patients at risk.
From Drug Targets to Metabolite Networks
Chemoproteomics is not limited to studying synthetic drugs. The same approaches work for endogenous metabolites, the small molecules that cells naturally produce and consume. Understanding which proteins interact with a given metabolite, and where on the protein the interaction happens, is critical for mapping metabolic regulation, yet these interaction networks have been notoriously difficult to study systematically.18PubMed Central. Targeted and proteome-wide analysis of metabolite-protein interactions
A label-free approach combining limited proteolysis with mass spectrometry was used to map metabolite-protein interactions proteome-wide in E. coli, revealing extensive networks of both known and previously unknown interactions and shedding light on enzyme promiscuity.19Cell. Quantitative Mapping of Protein-Metabolite Interactions in Cellular Extracts On the probe-based side, a platform called CATNIP was developed specifically to profile how different acyl-CoA metabolites interact with proteins. That work identified specific acyl-CoA “engagement signatures” for different proteins and uncovered a non-enzymatic acylation site in the acetyltransferase NAT10 that appears to be driven by acyl-CoA binding.20Cell Chemical Biology. Chemoproteomic Platform for Global Analysis of Acyl-CoA-Protein Interactions These metabolite-focused applications hint at a future where chemoproteomics maps not just drug targets but the full small-molecule interaction landscape of a cell.
Targeted Protein Degradation and the Expanding Druggable Space
Traditional drugs work by sitting in a protein’s active site and blocking its function. Targeted protein degradation takes a different approach: instead of blocking a protein, you tag it for destruction by the cell’s own disposal machinery. The most prominent strategy uses molecules called PROTACs, which are bifunctional compounds with one end that grabs the target protein and another end that recruits an E3 ubiquitin ligase, an enzyme that marks proteins for destruction.
Chemoproteomics has been instrumental in making this approach viable. By screening for covalent ligands that bind E3 ligases, researchers have discovered new E3 ligase recruiters that expand the toolkit available for degrader design. Chemoproteomic mapping has identified reactive cysteines within hundreds of E3 ligases that represent potential pharmacological handles.21Biochemistry. Ligandability of E3 Ligases for Targeted Protein Degradation Applications Looking forward, the same platforms are expected to drive discovery of molecular glue scaffolds and other proximity-based therapeutic strategies that go beyond degradation.22PubMed. Reimagining Druggability Using Chemoproteomic Platforms
Fragment-based ligand discovery paired with chemoproteomics is also pushing the boundaries of what is considered “druggable.” By screening libraries of small molecular fragments in native cellular environments and detecting binding chemoproteomic ally, researchers can survey ligandability across the proteome, identifying binding sites on proteins that were previously written off as undruggable.23PubMed Central. Proteome-Wide Fragment-Based Ligand and Target Discovery
Machine Learning Meets Chemoproteomic Data
As chemoproteomic experiments generate increasingly large and complex datasets, computational methods have become essential for separating real targets from noise. One approach, LiP-Quant, applies machine learning to prioritize true drug targets from limited-proteolysis experiments. The algorithm derives peptide attributes that distinguish genuine drug binding from background fluctuations, assigning a composite score whose dominant component (accounting for about 69% of the score weight) is how well a peptide’s behavior correlates with the expected dose-response curve of the drug.24Nature Communications. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes This kind of integration is a sign that chemoproteomics is maturing from a qualitative discovery tool into a quantitative platform where confidence in target calls can be formally scored.
Microbial and Gut Microbiome Applications
Chemoproteomics is not only a mammalian-cell enterprise. Activity-based profiling has been applied to bacterial proteomes and the gut microbiome, helping to elucidate biological processes in bacteria, discover new antibiotics, and characterize host-microbe interactions in physiologically relevant settings.25PubMed Central. Activity-based protein profiling in microbes and the gut microbiome
A concrete example comes from the study of bile salt hydrolases, enzymes produced by gut bacteria that modify bile acids and influence host metabolism and immunity. Chemoproteomic tools were developed to profile BSH activity in mouse gut microbiomes, and the probes revealed altered BSH activities in a mouse model of colitis, linking changes in microbial enzyme function to changes in bile acid metabolism during inflammatory bowel disease.26PubMed Central. Chemoproteomic Profiling of Gut Microbiota-Associated Bile Salt Hydrolase Activity This represents a significant expansion of the field’s scope, from pure drug discovery into disease biology and the microbiome.
Single-Cell and Spatial Resolution
Conventional chemoproteomics measures average protein activity across millions of cells. But tumors are heterogeneous, tissues are spatially organized, and averaging washes out the very differences that drive disease progression. Two frontiers are pushing past this limitation.
At the single-cell level, a platform using microfluidics-based single-cell capture converts the interactions of activity probes with proteins into amplifiable DNA barcodes, enabling multiplexed enzyme activity measurement directly in individual cells. Applied to breast cancer, this approach quantified a six-enzyme panel with known ties to cancer aggressiveness and identified increased enzyme activity in cell lines of increasing metastatic potential, as well as in primary patient-derived tumor cells and organoids.27PubMed Central. Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer
On the spatial side, researchers are developing chemical tools that detect and quantify protein functional states with subcellular resolution, enabling activity mapping within cell organelles, multi-cellular tissues, and whole organisms.28PubMed Central. Spatial Chemoproteomics for Mapping the Active Proteome Emerging techniques like CATCH (clearing-assisted tissue click chemistry) allow small-molecule drug imaging in situ, and the integration of these spatial readouts with single-cell omics platforms is expected to reshape how drug-target interactions are defined in living tissue.29PubMed. Deciphering Drug Targets and Actions with Single-Cell and Spatial Resolution
Phenotypic Screening and Target Identification in Tandem
Drug discovery often starts with phenotypic screening: you test thousands of compounds to see which ones kill cancer cells or reduce inflammation, and then you have to figure out why the winners work. Historically, identifying the molecular target after a phenotypic hit was slow and uncertain. Chemoproteomics has substantially compressed that timeline.
A recent study illustrates the pipeline. Researchers ran a phenotypic screen to find compounds that suppress NRF2-driven cancer, then used chemoproteomics to identify the target. The combination revealed that a compound called WS3 acts as an allosteric inhibitor of the 14-3-3 protein, selectively blocking NRF2 activity in tumor cells.30PubMed Central. Discovery of an allosteric 14-3-3 inhibitor for suppressing NRF2-driven cancer via phenotypic screening and chemoproteomic-based target deconvolution Without chemoproteomic target deconvolution, identifying an allosteric mechanism on an adapter protein like 14-3-3 would have been enormously difficult. The ability to go from a cell-based phenotype to a defined molecular target in a single integrated workflow is one of the field’s most tangible contributions to practical drug development.
Toward Clinical Chemoproteomics
Most chemoproteomic work still happens in cell lines and animal models. Translating these methods into the clinic, where you might profile drug-target engagement directly in patient tissues, remains an active area of exploration. The obstacles are both technical and practical: clinical samples are small, heterogeneous, and subject to strict handling constraints, and the analytical workflows need to be robust enough to deliver reproducible results under those conditions.
At the same time, the payoff would be substantial. Clinical chemoproteomics could verify that a drug actually hits its intended target in a patient’s tumor, distinguish responders from non-responders based on target engagement rather than tumor genetics alone, and identify off-target interactions that explain individual adverse reactions. The analytical infrastructure is getting close; the gap now is largely one of clinical validation and standardization of protocols suitable for hospital pathology labs rather than mass spectrometry core facilities.